Bisphenol S is a haemodialysis-associated xenobiotic that is less toxic than bisphenol A.

bisphenol A bisphenol S chronic kidney disease haemodiafiltration haemodialysis toxins xenobiotics

Journal

Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 30 08 2019
revised: 13 03 2020
accepted: 01 04 2020
entrez: 12 4 2021
pubmed: 13 4 2021
medline: 13 4 2021
Statut: epublish

Résumé

Bisphenol S (BPS) is a structural analogue of bisphenol A (BPA) that is found in the environment. BPS may accumulate in anuric patients due to decreased urinary excretion. The toxicity and health effects of BPS are poorly characterized. A cross-over study was performed using polynephron (PN) or polysulphone (PS) dialysers for a short (1 week each, 14 patients) or long (3 months each, 20 patients) period on each dialyser. Plasma BPA, BPS and hippuric acid were assessed by SRM mass spectrometry (SRM-MS). The biological significance of the BPS concentrations found was explored in cultured kidney tubular cells. In haemodiafiltration (HDF) patients, plasma BPS was 10-fold higher than in healthy subjects (0.53 ± 0.52 versus 0.05 ± 0.01 ng/mL; P = 0.0015), while BPA levels were 35-fold higher (13.23 ± 14.65 versus 0.37 ± 0.12 ng/mL; P = 0.007). Plasma hippuric acid decreased after an HDF session, while BPS and BPA did not. After 3 months of HDF with the same membranes, the BPS concentration was 1.01 ± 0.87 ng/mL for PN users and 0.62 ± 0.21 ng/mL for PS users (P non-statistically significant). BPS may be released from dialysis membranes, and dialysis patients display high BPS concentrations. However, BPS concentrations are lower than BPA concentrations and no BPS toxicity was observed at concentrations found in patient plasma.

Sections du résumé

BACKGROUND BACKGROUND
Bisphenol S (BPS) is a structural analogue of bisphenol A (BPA) that is found in the environment. BPS may accumulate in anuric patients due to decreased urinary excretion. The toxicity and health effects of BPS are poorly characterized.
METHODS METHODS
A cross-over study was performed using polynephron (PN) or polysulphone (PS) dialysers for a short (1 week each, 14 patients) or long (3 months each, 20 patients) period on each dialyser. Plasma BPA, BPS and hippuric acid were assessed by SRM mass spectrometry (SRM-MS). The biological significance of the BPS concentrations found was explored in cultured kidney tubular cells.
RESULTS RESULTS
In haemodiafiltration (HDF) patients, plasma BPS was 10-fold higher than in healthy subjects (0.53 ± 0.52 versus 0.05 ± 0.01 ng/mL; P = 0.0015), while BPA levels were 35-fold higher (13.23 ± 14.65 versus 0.37 ± 0.12 ng/mL; P = 0.007). Plasma hippuric acid decreased after an HDF session, while BPS and BPA did not. After 3 months of HDF with the same membranes, the BPS concentration was 1.01 ± 0.87 ng/mL for PN users and 0.62 ± 0.21 ng/mL for PS users (P non-statistically significant).
CONCLUSIONS CONCLUSIONS
BPS may be released from dialysis membranes, and dialysis patients display high BPS concentrations. However, BPS concentrations are lower than BPA concentrations and no BPS toxicity was observed at concentrations found in patient plasma.

Identifiants

pubmed: 33841860
doi: 10.1093/ckj/sfaa071
pii: sfaa071
pmc: PMC8023199
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1147-1155

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Références

Toxicology. 2019 Feb 1;413:48-55
pubmed: 30582956
Chem Res Toxicol. 2002 Oct;15(10):1281-7
pubmed: 12387626
Drug Chem Toxicol. 2011 Oct;34(4):454-61
pubmed: 21770746
Nephrol Dial Transplant. 2018 Oct 1;33(10):1712-1722
pubmed: 29425318
Sci Total Environ. 2019 Mar 10;655:607-613
pubmed: 30476841
Chemosphere. 2019 Apr;221:115-123
pubmed: 30639807
Environ Int. 2019 Feb;123:325-336
pubmed: 30557812
Environ Sci Technol. 2012 Aug 21;46(16):9138-45
pubmed: 22784190
Environ Pollut. 2018 Jun;237:1072-1079
pubmed: 29146198
Fertil Steril. 2015 Jan;103(1):11-21
pubmed: 25475787
Domest Anim Endocrinol. 2019 Jan;66:48-56
pubmed: 30439591
Environ Pollut. 2018 Dec;243(Pt B):1719-1726
pubmed: 30408859
Chemosphere. 2019 Feb;217:629-635
pubmed: 30447611
Environ Health Perspect. 2015 Jul;123(7):643-50
pubmed: 25775505
Environ Sci Pollut Res Int. 2019 Feb;26(4):3636-3642
pubmed: 30523531
Chemosphere. 2019 Apr;221:471-478
pubmed: 30654261
Environ Int. 2019 Feb;123:301-309
pubmed: 30553203
PLoS One. 2018 Mar 12;13(3):e0193288
pubmed: 29529055
Arh Hig Rada Toksikol. 2013 Jun;64(2):189-200
pubmed: 23819927
Rapid Commun Mass Spectrom. 2018 Mar 30;32(6):495-502
pubmed: 29280213
Environ Sci Pollut Res Int. 2018 Sep;25(27):26916-26926
pubmed: 30006815
Toxicol In Vitro. 2017 Jun;41:143-149
pubmed: 28259788
Sci Total Environ. 2018 Feb 15;615:87-98
pubmed: 28963899
J Am Soc Nephrol. 2016 May;27(5):1566-74
pubmed: 26432902
Chemosphere. 2016 Jun;152:383-91
pubmed: 26994432
Toxicol Appl Pharmacol. 2019 Mar 1;366:75-82
pubmed: 30684532
Environ Res. 2019 Mar;170:406-415
pubmed: 30623888
Hum Reprod. 2017 Jul 1;32(7):1465-1473
pubmed: 28482050
Chemosphere. 2019 Apr;221:500-510
pubmed: 30660906
Toxicol Appl Pharmacol. 2018 Nov 15;359:47-54
pubmed: 30240697
Environ Pollut. 2019 Mar;246:697-703
pubmed: 30616060
J Am Soc Nephrol. 2011 Jul;22(7):1315-25
pubmed: 21719790
Ecotoxicol Environ Saf. 2019 Dec 15;185:109684
pubmed: 31541948
Environ Toxicol. 2018 Mar;33(3):325-332
pubmed: 29214717
Arch Toxicol. 2000 Apr;74(2):99-105
pubmed: 10839477
Cell. 2017 Dec 14;171(7):1495-1507.e15
pubmed: 29224783

Auteurs

Sebastian Mas (S)

Renal, Vascular and Diabetes Laboratory, IIS-Fundación Jimenez Diaz UAM, Madrid, Spain.
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain.

Alberto Ruiz-Priego (A)

Renal, Vascular and Diabetes Laboratory, IIS-Fundación Jimenez Diaz UAM, Madrid, Spain.

Pedro Abaigar (P)

Division of Nephrology, Hospital Universitario de Burgos, Burgos, Spain.

Javier Santos (J)

Division of Nephrology, Hospital Universitario de Burgos, Burgos, Spain.

Vanesa Camarero (V)

Division of Nephrology, Hospital Universitario de Burgos, Burgos, Spain.

Jesús Egido (J)

Renal, Vascular and Diabetes Laboratory, IIS-Fundación Jimenez Diaz UAM, Madrid, Spain.
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain.
Division of Nephrology and Hypertension, IIS-Fundación Jimenez Diaz UAM, Madrid, Spain.
Department of Medicine, UAM, Madrid, Spain.

Alberto Ortiz (A)

Renal, Vascular and Diabetes Laboratory, IIS-Fundación Jimenez Diaz UAM, Madrid, Spain.
Division of Nephrology and Hypertension, IIS-Fundación Jimenez Diaz UAM, Madrid, Spain.
Department of Medicine, UAM, Madrid, Spain.
Spanish Kidney Research Network (REDINREN), Madrid, Spain.

Emilio Gonzalez-Parra (E)

Renal, Vascular and Diabetes Laboratory, IIS-Fundación Jimenez Diaz UAM, Madrid, Spain.
Division of Nephrology and Hypertension, IIS-Fundación Jimenez Diaz UAM, Madrid, Spain.
Department of Medicine, UAM, Madrid, Spain.
Spanish Kidney Research Network (REDINREN), Madrid, Spain.

Classifications MeSH